- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Growth at Reasonable Price
U.S. Pharmaceuticals & Biotech Growth at Reasonable Price
Results
43
43 companies
AVITA Medical
Market Cap: US$168.4m
Operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom.
RCEL
US$6.46
7D
-7.3%
1Y
-21.9%
Travere Therapeutics
Market Cap: US$1.9b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$16.80
7D
-16.1%
1Y
177.2%
Axsome Therapeutics
Market Cap: US$5.3b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$107.53
7D
-0.2%
1Y
40.5%
Ascendis Pharma
Market Cap: US$9.5b
Operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally.
ASND
US$157.60
7D
4.2%
1Y
30.1%
Ardelyx
Market Cap: US$808.7m
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$3.88
7D
7.2%
1Y
-50.3%
Evolus
Market Cap: US$644.8m
A performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.
EOLS
US$9.70
7D
-1.0%
1Y
-28.6%
Legend Biotech
Market Cap: US$5.1b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$27.78
7D
-12.6%
1Y
-38.5%
ACADIA Pharmaceuticals
Market Cap: US$2.9b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$22.26
7D
27.6%
1Y
50.5%
UroGen Pharma
Market Cap: US$454.2m
Engages in the development and commercialization of solutions for urothelial and specialty cancers.
URGN
US$7.31
7D
-29.6%
1Y
-44.7%
Soleno Therapeutics
Market Cap: US$3.8b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$75.01
7D
-2.3%
1Y
62.5%
Arcutis Biotherapeutics
Market Cap: US$1.6b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$14.11
7D
4.3%
1Y
53.4%
BioCryst Pharmaceuticals
Market Cap: US$2.1b
A biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases.
BCRX
US$10.24
7D
2.7%
1Y
63.1%
TriSalus Life Sciences
Market Cap: US$164.9m
Engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics for improving outcomes for patients with difficult-to-treat liver and pancreatic cancers.
TLSI
US$5.14
7D
2.4%
1Y
-47.8%
BeiGene
Market Cap: US$24.4b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$228.38
7D
-1.6%
1Y
32.1%
Vericel
Market Cap: US$2.1b
A commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
VCEL
US$42.48
7D
1.8%
1Y
-12.1%
Krystal Biotech
Market Cap: US$3.8b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$130.60
7D
-1.2%
1Y
-20.4%
Harmony Biosciences Holdings
Market Cap: US$2.0b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
HRMY
US$35.07
7D
3.0%
1Y
20.8%
Amicus Therapeutics
Market Cap: US$1.8b
A biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
FOLD
US$6.43
7D
7.5%
1Y
-32.8%
Fennec Pharmaceuticals
Market Cap: US$180.9m
Operates as a commercial stage biopharmaceutical company in the United States.
FENC
US$6.84
7D
15.0%
1Y
-2.8%
Mirum Pharmaceuticals
Market Cap: US$2.2b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$45.01
7D
1.7%
1Y
87.0%
Journey Medical
Market Cap: US$164.0m
Focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$6.94
7D
0.8%
1Y
101.0%
Day One Biopharmaceuticals
Market Cap: US$624.4m
A commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.
DAWN
US$6.25
7D
-3.1%
1Y
-61.3%
Alvotech
Market Cap: US$3.2b
Through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
ALVO
US$10.46
7D
11.5%
1Y
-22.5%
Harrow
Market Cap: US$940.2m
An eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
HROW
US$28.41
7D
16.4%
1Y
69.5%
Phathom Pharmaceuticals
Market Cap: US$242.4m
A biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
PHAT
US$4.09
7D
30.1%
1Y
-61.2%
Geron
Market Cap: US$770.7m
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
GERN
US$1.27
7D
7.6%
1Y
-66.7%
Apellis Pharmaceuticals
Market Cap: US$2.1b
A commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs.
APLS
US$17.45
7D
0.9%
1Y
-57.8%
Akebia Therapeutics
Market Cap: US$667.1m
A biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
AKBA
US$2.61
7D
2.4%
1Y
127.0%
Avadel Pharmaceuticals
Market Cap: US$860.0m
Operates as a biopharmaceutical company in the United States.
AVDL
US$9.01
7D
-4.0%
1Y
-41.8%
scPharmaceuticals
Market Cap: US$152.0m
A pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care.
SCPH
US$3.22
7D
32.0%
1Y
-32.2%
Halozyme Therapeutics
Market Cap: US$6.0b
A biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally.
HALO
US$52.02
7D
-21.0%
1Y
16.3%
Exelixis
Market Cap: US$12.6b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$45.40
7D
25.5%
1Y
117.1%
Sarepta Therapeutics
Market Cap: US$3.5b
A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
SRPT
US$36.43
7D
0.4%
1Y
-72.3%
Dynavax Technologies
Market Cap: US$1.1b
A commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally.
DVAX
US$9.67
7D
2.8%
1Y
-13.0%
Exact Sciences
Market Cap: US$10.6b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS
US$56.42
7D
9.3%
1Y
12.0%
Kiniksa Pharmaceuticals International
Market Cap: US$1.9b
A biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide.
KNSA
US$26.25
7D
0.8%
1Y
32.8%